leisure time -WSS

leisure time

author：hotspot 2025-10-02 09:21:59 - browse：49581

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： 2 million sign

focus

WSS

H.R. 3 is the wrong path to lower drug costs

The cancer stories no one wants to hear

China dismisses criticism of top diplomat's comments appearing to push for race

Pope Francis asks Church to identify 21st

Flint parents haunted by uncertainty, fears of lead poisoning

3 protesters arrested at Wimbledon after interrupting matches by throwing confetti on court

knowledge

leisure time

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

23andMe had bad news about my health. I wish a person had delivered it

Physicians aren't 'burning out.' They're suffering from moral injury

The high cost of giving birth even with insurance

Medicare slashes safety net hospital payments by nearly $1 billion

Medical records are filled with copy

The cancer stories no one wants to hear

Dobbs anniversary: the lost opportunity of abortion as health care

How to ethically and practically extend health care to all

explore

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Pentagon will tighten controls on classified information after Discord leak

FDA scientists endorse Pfizer/BioNTech Covid

EU moves toward latest gene techniques in food production to counter climate change, shortages

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

Adele warns fans about throwing things at performers onstage

hotspot

focus

focus

focus